156. Rett syndrome Clinical trials / Disease details

Clinical trials : 44 / Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01520363 (ClinicalTrials.gov)	March 2012	25/1/2012	Placebo Controlled Trial of Dextromethorphan in Rett Syndrome	Placebo Controlled Trial of Dextromethorphan in Rett Syndrome	Rett Syndrome	Drug: dextromethorphan;Drug: placebo	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	The Johns Hopkins Institute for Clinical and Translational Research (ICTR)	Completed	1 Year	10 Years	All	57	Phase 2	United States
2	NCT00069550 (ClinicalTrials.gov)	September 2004	29/9/2003	Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome	Pathogenesis of Rett Syndrome: Natural History and Treatment	Rett Syndrome	Drug: dextromethorphan;Drug: donepezil hydrochloride	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	NULL	Recruiting	1 Year	15 Years	Both	90	Phase 3	United States
3	NCT00593957 (ClinicalTrials.gov)	August 2004	4/1/2008	Trial of Dextromethorphan in Rett Syndrome	Trial of Dextromethorphan in Rett Syndrome	Rett Syndrome	Drug: Dextromethorphan	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	NULL	Terminated	2 Years	15 Years	All	38	Phase 2	United States
4	NCT00004807 (ClinicalTrials.gov)	January 1995	24/2/2000	Study of the Pathogenesis of Rett Syndrome		Rett Syndrome	Drug: dextromethorphan;Drug: topiramate;Drug: Donepezil	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Johns Hopkins University	Completed	N/A	45 Years	Both	120	N/A	NULL
5	EUCTR2008-005571-10-NO (EUCTR)		09/01/2009	DEXTROMETORPHAN IN RETT SYNDROME	DEXTROMETORPHAN IN RETT SYNDROME	Rett syndrome (RTT) is a neurological disorder with devastating consequences on the brain. It is characterized by stagnation of development followed by regression, both occurring between age 6 months and 3 years. The clinical picture is dominated by cognitive impairment, loss of communication skills, purposeful hand movements, hand stereotypies, progressive deceleration of head growth, and abnormal locomotion. RTT syndrome presently has no effective therapy other than pallitative care	Product Name: Dextromethorphan	Kennedy Krieger Inst. Johns Hopkins Medicine	NULL	NA			Female: yes Male: no	90	Phase 2	Norway